458 related articles for article (PubMed ID: 16128682)
1. Allopurinol safely and effectively optimizes tioguanine metabolites in inflammatory bowel disease patients not responding to azathioprine and mercaptopurine.
Sparrow MP; Hande SA; Friedman S; Lim WC; Reddy SI; Cao D; Hanauer SB
Aliment Pharmacol Ther; 2005 Sep; 22(5):441-6. PubMed ID: 16128682
[TBL] [Abstract][Full Text] [Related]
2. Effect of allopurinol on clinical outcomes in inflammatory bowel disease nonresponders to azathioprine or 6-mercaptopurine.
Sparrow MP; Hande SA; Friedman S; Cao D; Hanauer SB
Clin Gastroenterol Hepatol; 2007 Feb; 5(2):209-14. PubMed ID: 17296529
[TBL] [Abstract][Full Text] [Related]
3. The pharmacokinetic effect of discontinuation of mesalazine on mercaptopurine metabolite levels in inflammatory bowel disease patients.
Gilissen LP; Bierau J; Derijks LJ; Bos LP; Hooymans PM; van Gennip A; Stockbrügger RW; Engels LG
Aliment Pharmacol Ther; 2005 Oct; 22(7):605-11. PubMed ID: 16181300
[TBL] [Abstract][Full Text] [Related]
4. Azathioprine formulation optimizes metabolite profile in inflammatory bowel disease.
Stevens T; Achkar JP; Easley K; Brzezinski A; Lashner B
Aliment Pharmacol Ther; 2004 Sep; 20(6):601-6. PubMed ID: 15352907
[TBL] [Abstract][Full Text] [Related]
5. Thiopurine methyltransferase activity combined with 6-thioguanine metabolite levels predicts clinical response to thiopurines in patients with inflammatory bowel disease.
Kwan LY; Devlin SM; Mirocha JM; Papadakis KA
Dig Liver Dis; 2008 Jun; 40(6):425-32. PubMed ID: 18304898
[TBL] [Abstract][Full Text] [Related]
6. Allopurinol safely and effectively optimises thiopurine metabolites in patients with autoimmune hepatitis.
de Boer YS; van Gerven NM; de Boer NK; Mulder CJ; Bouma G; van Nieuwkerk CM
Aliment Pharmacol Ther; 2013 Mar; 37(6):640-6. PubMed ID: 23347359
[TBL] [Abstract][Full Text] [Related]
7. 6-tioguanine monitoring in steroid-dependent patients with inflammatory bowel diseases receiving azathioprine.
Roblin X; Serre-Debeauvais F; Phelip JM; Faucheron JL; Hardy G; Chartier A; Helluwaert F; Bessard G; Bonaz B
Aliment Pharmacol Ther; 2005 Apr; 21(7):829-39. PubMed ID: 15801918
[TBL] [Abstract][Full Text] [Related]
8. Azathioprine and 6-mercaptopurine pharmacogenetics and metabolite monitoring in inflammatory bowel disease.
Gearry RB; Barclay ML
J Gastroenterol Hepatol; 2005 Aug; 20(8):1149-57. PubMed ID: 16048561
[TBL] [Abstract][Full Text] [Related]
9. Allopurinol might improve response to azathioprine and 6-mercaptopurine by correcting an unfavorable metabolite ratio.
Gardiner SJ; Gearry RB; Burt MJ; Chalmers-Watson T; Chapman BA; Ross AG; Stedman CA; Huelsen A; Barclay ML
J Gastroenterol Hepatol; 2011 Jan; 26(1):49-54. PubMed ID: 21175793
[TBL] [Abstract][Full Text] [Related]
10. A prospective evaluation of the impact of allopurinol in pediatric and adult IBD patients with preferential metabolism of 6-mercaptopurine to 6-methylmercaptopurine.
Gerich ME; Quiros JA; Marcin JP; Tennyson L; Henthorn M; Prindiville TP
J Crohns Colitis; 2010 Nov; 4(5):546-52. PubMed ID: 21122558
[TBL] [Abstract][Full Text] [Related]
11. Observations on the use of allopurinol in combination with azathioprine or mercaptopurine.
Duley JA; Chocair PR; Florin TH
Aliment Pharmacol Ther; 2005 Dec; 22(11-12):1161-2. PubMed ID: 16305731
[No Abstract] [Full Text] [Related]
12. A 6-thioguanine nucleotide threshold level of 400 pmol/8 x 10(8) erythrocytes predicts azathioprine refractoriness in patients with inflammatory bowel disease and normal TPMT activity.
Roblin X; Peyrin-Biroulet L; Phelip JM; Nancey S; Flourie B
Am J Gastroenterol; 2008 Dec; 103(12):3115-22. PubMed ID: 19086961
[TBL] [Abstract][Full Text] [Related]
13. Adverse events leading to modification of therapy in a large cohort of patients with inflammatory bowel disease.
Hindorf U; Lindqvist M; Hildebrand H; Fagerberg U; Almer S
Aliment Pharmacol Ther; 2006 Jul; 24(2):331-42. PubMed ID: 16842460
[TBL] [Abstract][Full Text] [Related]
14. Thiopurine dose in intermediate and normal metabolizers of thiopurine methyltransferase may differ three-fold.
Gardiner SJ; Gearry RB; Begg EJ; Zhang M; Barclay ML
Clin Gastroenterol Hepatol; 2008 Jun; 6(6):654-60; quiz 604. PubMed ID: 18467186
[TBL] [Abstract][Full Text] [Related]
15. The role of thiopurine metabolite monitoring in inflammatory bowel disease.
Beswick L; Friedman AB; Sparrow MP
Expert Rev Gastroenterol Hepatol; 2014 May; 8(4):383-92. PubMed ID: 24684593
[TBL] [Abstract][Full Text] [Related]
16. Monitoring of long-term thiopurine therapy among adults with inflammatory bowel disease.
Hindorf U; Lyrenäs E; Nilsson A; Schmiegelow K
Scand J Gastroenterol; 2004 Nov; 39(11):1105-12. PubMed ID: 15545169
[TBL] [Abstract][Full Text] [Related]
17. On the limitation of 6-tioguaninenucleotide monitoring during tioguanine treatment.
de Boer NK; de Graaf P; Wilhelm AJ; Mulder CJ; van Bodegraven AA
Aliment Pharmacol Ther; 2005 Sep; 22(5):447-51. PubMed ID: 16128683
[TBL] [Abstract][Full Text] [Related]
18. Low-dose azathioprine or mercaptopurine in combination with allopurinol can bypass many adverse drug reactions in patients with inflammatory bowel disease.
Ansari A; Patel N; Sanderson J; O'Donohue J; Duley JA; Florin TH
Aliment Pharmacol Ther; 2010 Mar; 31(6):640-7. PubMed ID: 20015102
[TBL] [Abstract][Full Text] [Related]
19. Thiopurine methyltransferase and 6-thioguanine nucleotide measurement: early experience of use in clinical practice.
Gearry RB; Barclay ML; Roberts RL; Harraway J; Zhang M; Pike LS; George PM; Florkowski CM
Intern Med J; 2005 Oct; 35(10):580-5. PubMed ID: 16207256
[TBL] [Abstract][Full Text] [Related]
20. Thiopurines in inflammatory bowel disease: pharmacogenetics, therapeutic drug monitoring and clinical recommendations.
Al Hadithy AF; de Boer NK; Derijks LJ; Escher JC; Mulder CJ; Brouwers JR
Dig Liver Dis; 2005 Apr; 37(4):282-97. PubMed ID: 15788214
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
